BIM
INO icon

Bogle Investment Management’s Inovio Pharmaceuticals INO Stock Holding History

Bogle Investment Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,601
Closed -$656K – 312
2018
Q1 		$656K Buy
+11,601
New +$628K 0.05% 259

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bogle Investment Management's INO Position: Q2 2018 in Review

Bogle Investment Management sold out of Inovio Pharmaceuticals (INO) in Q2 2018, closing a stake of 11,601 shares — an estimated $656K sold.

Bogle Investment Management first reported a position in INO in Q1 2018 and held it in 1 quarter. The position peaked at $656K in Q1 2018. 126 funds tracked by Wall St. Rank hold INO as of Q2 2018.

  • Bogle Investment Management reported no remaining Inovio Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Bogle Investment Management sold 11,601 Inovio Pharmaceuticals shares in Q2 2018, an estimated $656K.
  • Bogle Investment Management first reported a position in Inovio Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Bogle Investment Management's Inovio Pharmaceuticals position peaked at $656K in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2018.

Based on Bogle Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.